BPG is committed to discovery and dissemination of knowledge
Featured Articles
3/5/2025 9:46:23 AM | Browse: 269 | Download: 656
 |
Received |
|
2024-12-31 03:45 |
|
Peer-Review Started |
|
2024-12-31 03:45 |
|
First Decision by Editorial Office Director |
|
2025-02-14 09:18 |
|
Return for Revision |
|
2025-02-14 09:18 |
|
Revised |
|
2025-02-23 08:02 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-03-03 02:44 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-03-04 12:32 |
|
Articles in Press |
|
2025-03-04 12:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-03-05 05:46 |
|
Publish the Manuscript Online |
|
2025-03-05 09:35 |
| ISSN |
1949-8454 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Minireviews |
| Article Title |
Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Samira Farhadi, Saeed Mohammadi, Abdulaziz Y AlKindi and Issa S Al-Amri |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Issa S Al-Amri, Associate Professor, PhD, Department of Biological Sciences and Chemistry, College of Arts and Sciences,, University of Nizwa, P.O. Box 33, Nizwa 616, Ad Dākhilīyah, Oman. issa.alamri@unizwa.edu.om |
| Key Words |
Alcohol-associated liver disease; Elafibranor; PPARα/PPARδ agonist; Macrophages; Liver fibrosis; Inflammatory responses |
| Core Tip |
Macrophages play a central role in the progression of alcohol-associated liver disease (ALD), from initial liver injury to advanced stages like cirrhosis. Elafibranor (EFN), a dual PPARα/δ agonist, offers a promising therapeutic approach by reducing liver fibrosis, inhibiting macrophage activation, and suppressing TLR4/NF-κB inflammatory pathways. Additionally, EFN strengthens intestinal barrier function, addressing key drivers of ALD. With its dual anti-inflammatory and fibrosis-reducing effects, EFN holds potential for ALD and other liver diseases characterized by chronic inflammation and fibrosis. Further research is needed to validate its clinical applications. |
| Publish Date |
2025-03-05 09:35 |
| Citation |
Farhadi S, Mohammadi S, AlKindi AY, Al-Amri IS. Therapeutic potential of elafibranor in alcohol-associated liver disease: Insights into macrophage modulation and fibrosis reduction. World J Biol Chem 2025; 16(1): 104535 |
| URL |
https://www.wjgnet.com/1949-8454/full/v16/i1/104535.htm |
| DOI |
https://dx.doi.org/10.4331/wjbc.v16.i1.104535 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
